Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

New data on Eloxatin(R), Taxotere(R) and on three investigational agents (VEGF Trap, S-1 and TroVax(R)) will be presented at the 43rd annual ASCO meeting

BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that a total of 375 abstracts indicative of its oncology commitment have been accepted for the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (June 1-5, 2007). The results from key studies involving the company's leading anticancer agents, Eloxatin(R) (oxaliplatin injection) and Taxotere(R) (docetaxel injection concentrate), will be presented alongside clinical trial data examining investigational agents, aflibercept (VEGF Trap), S-1 (oral fluoropyrimidine) and TroVax(R) (Therapeutic Cancer Vaccine).

Of the abstracts which have been accepted, 129 focus on Eloxatin(R), 214 on Taxotere(R), 29 on S-1, two on VEGF Trap and one on TroVax(R). One hundred and ninety three Eloxatin(R) and Taxotere(R) abstracts were also accepted for presentation at the scientific sessions, with five Eloxatin(R) and 15 Taxotere(R) abstracts to be oral communications, including one Eloxatin(R) presentation at the ASCO plenary session.

The key results presented with Eloxatin(R)-based treatment (in combination with 5FU/LV) cover clinical trials in the adjuvant (post-surgery) colon cancer (MOSAIC study) and the metastatic (advanced) colorectal cancer (NCCTG/N9741study, EORTC40983/EPOC study) settings.

Data looking at Taxotere(R)-based regimens in adjuvant and in metastatic breast cancer will be presented during the meeting.

Two phase II studies examined aflibercept (VEGF Trap) as a single agent in recurrent ovarian and lung cancers. VEGF Trap is an anti-angiogenic agent that blocks the Vascular Endothelial Growth Factor (VEGF), and is currently being investigated to assess its use in stopping tumor growth. Aflibercept is in phase
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/26/2008)...swire/ -- Children whose eyes are misaligned and p...f developing mental illness by early adulthood, ac...hed this month in Pediatrics , the official journa... The retrospective study examined the medical rec...yes) and compared them with records of children ma...
(Date:11/25/2008)... , Audio and Web Video Resources to accompany ...log. Please see the bottom of this release for det...RNewswire-USNewswire/ -- A Mayo Clinic study shows... having a stroke -- and as a result -- delay seeki...ndings appear in the current issue of Emergency Me...
(Date:11/25/2008)...swire/ -- Proteolix, Inc., a,leader in the discov...get,protein degradation pathways in cancer and au... two ongoing Phase 2 clinical trials of carfilzomi...coming 50th Annual Meeting of the,American Societ...n a new class,of specific proteasome inhibitors a...
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 1Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 2Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 1Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 1Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 1Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 2Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 4Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 5Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 6Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 7Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 8
...--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical...t of DNA vaccines,for cancers and infectious disea...calized cancers, announced today the company,deliv...esults and,new device innovations relating to its ...t the 10th Annual Meeting of the American,Society ...
...fficacy and Markers Demonstrated in Combination Tr...stCall/ --,EntreMed, Inc. , a clinical-stage pharm...y for the treatment of cancer and inflammatory,dis...from the Phase,1b study with Panzem(R) NCD (2ME2 o... (paclitaxel) in patients with metastatic,breast c...
Other Medicine Technology:Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 2Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 3Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 4Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 5Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 2Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 3Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 4
(Date:12/2/2008).... 2 In response to the commentary ...ent Respiratory Infections, and the Vitamin D Defi...well known supplement experts, Nordic Naturals ann...no threat or compromise to consumers and actually ...low in natural Vitamin A. According to Karin Yien,...
(Date:12/2/2008)...re/ -- The Healthcare group at Frost & Sulliva... to announce that it will be,hosting an interacti...diology,Markets on 11 December 2008 at 3pm GMT. ,...h/20081117/FSLOGO ) , With most diagnostic ...ndors in Europe are faced with an immense challeng...
(Date:12/2/2008)...Dec. 2 Internationally recognized,...nvited speaker for this,year,s annual meeting of ... (Photo: http://www.newscom.com/cgi-bin/prnh/200... minimally invasive (or ,Goldilocks,) anesthesia,...K 101, minimally invasive,anesthesia for minimall...
(Date:12/2/2008)... World Wide Dictation Service, one of the premier...cription, and legal dictation transcription, has ..., a non-profit organization geared to the betterme...r families throughout Lower Westchester County, Ne...WEB) December 3, 2008 -- World Wide Dictation Serv...
Breaking Medicine News(10 mins):Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2
...ity to develop 'much cheaper' drugs to combat HIV/...available first and second line treatment of the d...man in the country. Stating that the Indian compan...ging down the price of first and second line HIV d...
...om one evening in May, hoteliers, ambassadors, cel...ie gras, oysters and sushi while they talked about...skan king crab, French wine and melt-in-your-mouth...assembled crowd discussed ways of putting Bangkok ...
...t bread companies is not happy with the proposal t... acid. They are petitioning the state and federal/...e of such a proposal is to enhance the foliate lev... folic acid fortification will help offset birth d...
...er Surayud Chulanont, has defended his government'...ns of three patented// drugs-in spite of US worrie.... "We still defend what we have done, and we can ...ntries as well the world community," Surayud was q...
Other Medicine News:Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Thailand Unfazed As US Worries Over Copyright Violations 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: